Ravindra Majeti -Assistant Professor, Division of Hematology, Stanford Cancer Center, Stanford Institute for Stem Cell Biology and Regenerative Medicine.
CD47 is a new potential target for elimination of leukemia-initiating cells in hematological malignancies.
We demonstrate not only that CD47 is more highly expressed on AML LSC compared to normal HSC and MPP but also that this differential expression can be used to separate normal HSC/MPP from leukemia cells.
Majeti R, et al. Cell 2009;138:286
Even CD47 “covers” conventional (CD34+/CD38-) leukemia stem cells in AML, it equally expressed in other leukemic cells.
This talk was recorded at the 2010 AACR annual meeting April 17.
If you’re looking for postdoc position, you should consider his lab. Apply now!